Announcement Regarding Publication of XPRIZE Healthspan Semi-Final Clinical Trial Results

On May 14, 2026, Tohoku University, Hiroshima University, and Tokai University, with which Renascience Inc. is conducting joint research, announced the results of the XPRIZE Healthspan Semi-Final clinical trial.

In this clinical trial, administration of RS5614 to elderly participants for four months confirmed that there were no safety concerns and demonstrated significant anti-aging effects, including rejuvenation of biological age.

For further details, please refer to the following website.

Tohoku University Press Release
https://www.tohoku.ac.jp/japanese/newimg/pressimg/tohokuuniv_press20260514_02web_tm5614.pdf